<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Clintel | Clinical Pharmacology & Pharmacometrics</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet">
  <link rel="stylesheet" href="style.css" />
</head>
<body>

  <header class="bg-primary text-white text-center py-5">
    <div class="container">
      <img src="assets/abrarali.jpg" class="rounded-circle mb-3" alt="Abrarali Attarwala" width="150" height="150">
      <h1>Clintel</h1>
      <p class="lead">Expert Clinical Pharmacology & Pharmacometrics Services</p>
      <p class="text-white-50">Founded by Abrarali Attarwala</p>
    </div>
  </header>

  <section class="py-5 bg-light">
    <div class="container">
      <h2>About Us</h2>
      <p>
        Clintel is a consultancy dedicated to advancing model-informed drug development (MIDD) through expert clinical pharmacology and pharmacometrics strategies. Founded by Abrarali Attarwala, a seasoned Clinical Pharmacologist with over a decade of experience, Clintel bridges the gap between data and decision-making in the pharmaceutical and biotech sectors.
      </p>
    </div>
  </section>

  <section class="py-5">
    <div class="container">
      <h2>Our Services</h2>

      <div class="mb-4">
        <h5>Clinical Pharmacology Strategy</h5>
        <p>
          We provide strategic guidance throughout the drug development lifecycle—from early-phase studies to regulatory submissions. Our tailored strategies optimize pharmacological insights for robust and efficient development programs.
        </p>
      </div>

      <div class="mb-4">
        <h5>Population PK/PD Modeling</h5>
        <p>
          We develop population pharmacokinetic/pharmacodynamic (PK/PD) models to support dose selection, quantify variability, and design efficient trials. These models form the backbone of data-driven therapeutic decisions.
        </p>
      </div>

      <div class="mb-4">
        <h5>PBPK Modeling</h5>
        <p>
          Physiologically Based Pharmacokinetic (PBPK) modeling is used to simulate drug behavior in specific populations and predict complex interactions. It enables confident extrapolation to special populations like pediatrics, geriatrics, and those with hepatic or renal impairment.
        </p>
      </div>

      <div class="mb-4">
        <h5>Model-Informed Drug Development (MIDD)</h5>
        <p>
          MIDD integrates data across studies to inform key decisions, minimize trial burden, and accelerate development timelines. We use simulation and modeling tools to reduce uncertainty and improve regulatory success rates.
        </p>
      </div>

    </div>
  </section>

  <section class="py-5 bg-light">
    <div class="container">
      <h2>Contact</h2>
      <p>Email: <a href="mailto:contact@clintelconsulting.com">contact@clintelconsulting.com</a></p>
      <p>Founder: Abrarali Attarwala</p>
      <p>LinkedIn: <a href="https://www.linkedin.com/in/abrarali-attarwala" target="_blank">/abrarali-attarwala</a></p>
    </div>
  </section>

  <footer class="bg-dark text-white text-center py-3">
    <p class="mb-0">© 2025 Clintel. All rights reserved.</p>
  </footer>

</body>
</html>
